QR код

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study

Abstract Introduction Clinical trials have demonstrated prolonged survival associated with niraparib first-line maintenance (1LM) therapy, compared with placebo, for patients with ovarian cancer (OC). However, data are limited on real-world 1LM niraparib monotherapy use, particularly as switch 1LM,...

Повний опис

Збережено в:
Автори: Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Формат: Artigo
Мова:Inglês
Опубліковано: Adis, Springer Healthcare 2024-07-01
Серія:Oncology and Therapy
Предмети:
First-line maintenance therapy
Niraparib
Ovarian cancer
Real-world
Switch maintenance
Time to next treatment
Онлайн доступ:https://doi.org/10.1007/s40487-024-00281-8
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси